Prostate Cancer

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data on the role of AI in care.

I was diagnosed with testicular cancer at 20. I’ve learned to embrace the pauses in life and stand proud as a survivor who won’t be ignored.

Dr. Ravi Munver explained that, for patients who are recently diagnosed with prostate cancer, it is important to explore treatment option with their care.

Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion.

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.

Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.

Dr. Alicia Morgans discussed complications associated with ADT in prostate cancer, and how men can still maintain quality of life regardless.

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining treatment with PARP inhibitors.

A powerful new ally is emerging in cancer care: artificial intelligence.

The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate cancer, respectively.

Dr. Kelly Stratton answered the most frequently asked questions in prostate cancer regarding localized prostate cancer care, including surgery and focal therapy.

Dr. Kelly Stratton answers the most frequently asked questions in prostate cancer regarding risk for recurrence, progression and treatment options.

Managing fatigue, sleep, urinary symptoms and depression is key to improving cognitive function in those receiving radiation therapy for prostate cancer.

The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases.

Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.

Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal cancers.

As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical challenges.

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.